Since the same perspective was provided by the assay using the administration of a recombinant chimeric protein inhibitor for FasL/Fas interaction (Fig. 1B), this effect was not due to the other effects mediated by gld/gld mutation or genetic background before the viral infection. The gene discussed is FAS; the disease is viral infectious disease.